Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 7/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL895866 | 0.78 | KCNQ2 (0.42) | AKR1C3AKR1C2LMNASMN1; SMN2HTT | |
| SCHEMBL1333007 | 0.73 | — | — | |
| SCHEMBL895915 | 0.72 | SMN1; SMN2 (0.41) | GAATHRBLMNASMN1; SMN2CYP2C19 | |
| SCHEMBL1800612 | 0.72 | AKR1C3 (0.42) | AKR1C3AKR1C2GAATHRBLMNA | |
| SCHEMBL895816 | 0.71 | AKR1C3 (0.41) | AKR1C3AKR1C2GAATHRBLMNA | |
| SCHEMBL895506 | 0.71 | L3MBTL1 (0.42) | AKR1C3AKR1C2LMNAAKR1C1PTGS1 | |
| SCHEMBL896254 | 0.70 | MEN1 (0.41) | GAALMNASMN1; SMN2CYP2C9CYP2C19 | |
| SCHEMBL895966 | 0.69 | LMNA (0.40) | AKR1C3AKR1C2GAATHRBLMNA | |
| SCHEMBL895856 | 0.69 | S1PR3 (0.43) | AKR1C3AKR1C2 | |
| SCHEMBL896615 | 0.68 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083605-A1 | PYRIDAZINE COMPOUND AND USE THEREOF | PLPBP, PNPO, PDXK | AKR1C3 2050/4885AKR1C2 2260/4885GAA 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.